3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urologic Diseases
1
Nephritis
1
Lymphoma, Non-Hodgkin
1
Kidney Diseases
1
Immune System Diseases
1
Heart Failure
1
Glomerulonephritis, IGA
1
Glomerulonephritis
1
Cardiomyopathies
1
Autoimmune Diseases
1
Interventions
Cyclophosphamide
8
fludarabine phosphate
6
fludarabine
5
Bendamustine Hydrochloride
4
Busulfan
3
AP 1903 reagent
3
pembrolizumab
2
Tacrolimus
2
Mycophenolic Acid
2
thymoglobulin
1
pimonidazole
1
palbociclib
1
ibritumomab tiuxetan
1
Valsartan
1
Telemedicine
1
Surveys and Questionnaires
1
Rivaroxaban
1
Rituximab
1
Radiotherapy
1
Plasmalyte A
1
Pharmacogenomic Testing
1
Melphalan
1
Hydroxychloroquine
1
Etoposide
1
Dimethyl Sulfoxide
1
Cytarabine
1
Carmustine
1
Bone Marrow Transplantation
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Immune System Diseases
×
Valsartan
×
Clear all
NCT02765594
2017-09-20
HCQIgAN
Peking Union Medical College Hospital
Phase 4
Unknown
98 enrolled